{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T01:38:35Z","timestamp":1792805915396,"version":"4.5.0"},"reference-count":71,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2024,6,28]],"date-time":"2024-06-28T00:00:00Z","timestamp":1719532800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,6,28]],"date-time":"2024-06-28T00:00:00Z","timestamp":1719532800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82360148"],"award-info":[{"award-number":["82360148"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82300805"],"award-info":[{"award-number":["82300805"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004001","name":"Guizhou Provincial Science and Technology Department","doi-asserted-by":"publisher","award":["QKHPTRC2018-5636-2; QKHCG2023-ZD010"],"award-info":[{"award-number":["QKHPTRC2018-5636-2; QKHCG2023-ZD010"]}],"id":[{"id":"10.13039\/501100004001","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Basic Research Plan of Guizhou Province in 2023","award":["(QKH-ZK[2023] General 218"],"award-info":[{"award-number":["(QKH-ZK[2023] General 218"]}]},{"name":"Talent Fund of Guizhou provincial People\u2019s Hospital","award":["[2022]-1"],"award-info":[{"award-number":["[2022]-1"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Hematol"],"published-print":{"date-parts":[[2024,12]]},"DOI":"10.1007\/s00277-024-05860-3","type":"journal-article","created":{"date-parts":[[2024,6,28]],"date-time":"2024-06-28T17:19:35Z","timestamp":1719595175000},"page":"5007-5018","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":15,"title":["Update on kidney injury caused by multiple myeloma"],"prefix":"10.1007","volume":"103","author":[{"given":"Linhui","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chen","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haiyan","family":"Song","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing","family":"Yuan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan","family":"Zha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yiyao","family":"Deng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,6,28]]},"reference":[{"key":"5860_CR1","unstructured":"SEER. Cancer stat facts: myeloma. Available at: https:\/\/seer.cancer.gov\/statfacts\/html\/mulmy.html. Accessed 25 Oct 2024"},{"key":"5860_CR2","doi-asserted-by":"publisher","unstructured":"Siegel RL, Miller KD, Wagle NS, Jemal A (2023) Cancer statistics, 2023. CA Cancer J Clin 73(1):17\u201348. https:\/\/doi.org\/10.3322\/caac.21763","DOI":"10.3322\/caac.21763"},{"key":"5860_CR3","doi-asserted-by":"publisher","first-page":"1770","DOI":"10.1056\/NEJMra1613984","volume":"376","author":"MH Rosner","year":"2017","unstructured":"Rosner MH, Perazella MA (2017) Acute kidney injury in patients with cancer. N Engl J Med 376:1770\u20131781. https:\/\/doi.org\/10.1056\/NEJMra1613984","journal-title":"N Engl J Med"},{"key":"5860_CR4","doi-asserted-by":"publisher","first-page":"e7819","DOI":"10.7717\/peerj.7819","volume":"7","author":"T Reiter","year":"2019","unstructured":"Reiter T et al (2019) Structural analysis of urinary light chains and proteomic analysis of hyaline tubular casts in light chain associated kidney disorders. PeerJ 7:e7819. https:\/\/doi.org\/10.7717\/peerj.7819","journal-title":"PeerJ"},{"key":"5860_CR5","doi-asserted-by":"publisher","first-page":"2792","DOI":"10.1172\/jci125517","volume":"129","author":"WZ Ying","year":"2019","unstructured":"Ying WZ et al (2019) Immunoglobulin light chains generate proinflammatory and profibrotic kidney injury. J Clin Invest 129:2792\u20132806. https:\/\/doi.org\/10.1172\/jci125517","journal-title":"J Clin Invest"},{"key":"5860_CR6","doi-asserted-by":"publisher","first-page":"1833","DOI":"10.1182\/blood.2019003807","volume":"135","author":"V Royal","year":"2020","unstructured":"Royal V et al (2020) Clinicopathologic predictors of renal outcomes in light chain cast nephropathy: a multicenter retrospective study. Blood 135:1833\u20131846. https:\/\/doi.org\/10.1182\/blood.2019003807","journal-title":"Blood"},{"key":"5860_CR7","doi-asserted-by":"publisher","first-page":"1014","DOI":"10.1093\/ckj\/sfad022","volume":"16","author":"NR Terrades","year":"2023","unstructured":"Terrades NR et al (2023) Role of light chain clearance in the recovery of renal function in multiple myeloma: another point of view. Clin Kidney J 16:1014\u20131021. https:\/\/doi.org\/10.1093\/ckj\/sfad022","journal-title":"Clin Kidney J"},{"key":"5860_CR8","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1002\/mc.23272","volume":"60","author":"P \u0141acina","year":"2021","unstructured":"\u0141acina P et al (2021) Association of RANK and RANKL gene polymorphism with survival and calcium levels in multiple myeloma. Mol Carcinog 60:106\u2013112. https:\/\/doi.org\/10.1002\/mc.23272","journal-title":"Mol Carcinog"},{"key":"5860_CR9","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1016\/j.metabol.2017.11.012","volume":"80","author":"E Terpos","year":"2018","unstructured":"Terpos E, Christoulas D, Gavriatopoulou M (2018) Biology and treatment of myeloma related bone disease. Metabolism 80:80\u201390. https:\/\/doi.org\/10.1016\/j.metabol.2017.11.012","journal-title":"Metabolism"},{"key":"5860_CR10","doi-asserted-by":"publisher","first-page":"214","DOI":"10.1016\/j.canlet.2017.11.020","volume":"414","author":"J Hu","year":"2018","unstructured":"Hu J, Hu WX (2018) Targeting signaling pathways in multiple myeloma: pathogenesis and implication for treatments. Cancer Lett 414:214\u2013221. https:\/\/doi.org\/10.1016\/j.canlet.2017.11.020","journal-title":"Cancer Lett"},{"key":"5860_CR11","doi-asserted-by":"publisher","unstructured":"Mukkamalla SKR, Malipeddi D (2021) Myeloma bone disease: a comprehensive review. Int J Mol Sci 22. https:\/\/doi.org\/10.3390\/ijms22126208","DOI":"10.3390\/ijms22126208"},{"key":"5860_CR12","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1172\/jci115305","volume":"88","author":"R Bataille","year":"1991","unstructured":"Bataille R et al (1991) Recruitment of new osteoblasts and osteoclasts is the earliest critical event in the pathogenesis of human multiple myeloma. J Clin Invest 88:62\u201366. https:\/\/doi.org\/10.1172\/jci115305","journal-title":"J Clin Invest"},{"key":"5860_CR13","doi-asserted-by":"publisher","first-page":"3485","DOI":"10.1111\/bcp.14780","volume":"87","author":"C de Roij van Zuijdewijn","year":"2021","unstructured":"de Roij van Zuijdewijn C, van Dorp W, Florquin S, Roelofs J, Verburgh K (2021) Bisphosphonate nephropathy: a case series and review of the literature. Br J Clin Pharmacol 87:3485\u20133491. https:\/\/doi.org\/10.1111\/bcp.14780","journal-title":"Br J Clin Pharmacol"},{"key":"5860_CR14","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1159\/000094676","volume":"116","author":"D Henrich","year":"2006","unstructured":"Henrich D, Hoffmann M, Uppenkamp M, Bergner R (2006) Ibandronate for the treatment of hypercalcemia or nephrocalcinosis in patients with multiple myeloma and acute renal failure: case reports. Acta Haematol 116:165\u2013172. https:\/\/doi.org\/10.1159\/000094676","journal-title":"Acta Haematol"},{"key":"5860_CR15","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1016\/j.ajpath.2011.09.017","volume":"180","author":"WZ Ying","year":"2012","unstructured":"Ying WZ, Wang PX, Sanders PW (2012) Pivotal role of apoptosis signal-regulating kinase 1 in monoclonal free light chain-mediated apoptosis. Am J Pathol 180:41\u201347. https:\/\/doi.org\/10.1016\/j.ajpath.2011.09.017","journal-title":"Am J Pathol"},{"key":"5860_CR16","doi-asserted-by":"publisher","first-page":"4368","DOI":"10.1093\/ndt\/gfs261","volume":"27","author":"C El Hamel","year":"2012","unstructured":"El Hamel C et al (2012) Specific impairment of proximal tubular cell proliferation by a monoclonal \u03ba light chain responsible for Fanconi syndrome. Nephrol Dial Transplant 27:4368\u20134377. https:\/\/doi.org\/10.1093\/ndt\/gfs261","journal-title":"Nephrol Dial Transplant"},{"key":"5860_CR17","doi-asserted-by":"publisher","first-page":"e70276","DOI":"10.1371\/journal.pone.0070276","volume":"8","author":"S Sengul","year":"2013","unstructured":"Sengul S, Erturk S, Khan AM, Batuman V (2013) Receptor-associated protein blocks internalization and cytotoxicity of myeloma light chain in cultured human proximal tubular cells. PLoS ONE 8:e70276. https:\/\/doi.org\/10.1371\/journal.pone.0070276","journal-title":"PLoS ONE"},{"key":"5860_CR18","doi-asserted-by":"publisher","first-page":"2049","DOI":"10.1681\/asn.2015050581","volume":"27","author":"A Luciani","year":"2016","unstructured":"Luciani A et al (2016) Impaired lysosomal function underlies monoclonal light chain-associated renal Fanconi syndrome. J Am Soc Nephrol 27:2049\u20132061. https:\/\/doi.org\/10.1681\/asn.2015050581","journal-title":"J Am Soc Nephrol"},{"key":"5860_CR19","doi-asserted-by":"publisher","first-page":"2288","DOI":"10.2215\/cjn.02560316","volume":"11","author":"M Doshi","year":"2016","unstructured":"Doshi M, Lahoti A, Danesh FR, Batuman V, Sanders PW (2016) Paraprotein-related kidney disease: kidney injury from paraproteins-what determines the site of injury? Clin J Am Soc Nephrol 11:2288\u20132294. https:\/\/doi.org\/10.2215\/cjn.02560316","journal-title":"Clin J Am Soc Nephrol"},{"key":"5860_CR20","doi-asserted-by":"publisher","first-page":"2127","DOI":"10.1007\/s40620-022-01362-5","volume":"35","author":"G Terinte-Balcan","year":"2022","unstructured":"Terinte-Balcan G, Stefan G, Stancu S, Wang S, Gherghiceanu M (2022) Crystal-induced collapsing podocytopathy and light chain proximal tubulopathy in monoclonal gammopathy of renal significance. J Nephrol 35:2127\u20132130. https:\/\/doi.org\/10.1007\/s40620-022-01362-5","journal-title":"J Nephrol"},{"key":"5860_CR21","doi-asserted-by":"publisher","first-page":"1379","DOI":"10.1016\/j.ekir.2021.02.014","volume":"6","author":"GA Herrera","year":"2021","unstructured":"Herrera GA et al (2021) Glomerulopathic light chain-mesangial cell interactions: sortilin-related receptor (SORL1) and signaling. Kidney Int Rep 6:1379\u20131396. https:\/\/doi.org\/10.1016\/j.ekir.2021.02.014","journal-title":"Kidney Int Rep"},{"key":"5860_CR22","doi-asserted-by":"publisher","first-page":"102926","DOI":"10.1016\/j.critrevonc.2020.102926","volume":"149","author":"C Zuo","year":"2020","unstructured":"Zuo C, Zhu Y, Xu G (2020) An update to the pathogenesis for monoclonal gammopathy of renal significance. Crit Rev Oncol Hematol 149:102926. https:\/\/doi.org\/10.1016\/j.critrevonc.2020.102926","journal-title":"Crit Rev Oncol Hematol"},{"key":"5860_CR23","doi-asserted-by":"publisher","first-page":"611","DOI":"10.1053\/j.ajkd.2022.08.025","volume":"81","author":"L Bu","year":"2023","unstructured":"Bu L et al (2023) Light chain-only immunotactoid glomerulopathy: a case report. Am J Kidney Dis 81:611\u2013615. https:\/\/doi.org\/10.1053\/j.ajkd.2022.08.025","journal-title":"Am J Kidney Dis"},{"key":"5860_CR24","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1038\/s41408-022-00643-3","volume":"12","author":"J Blad\u00e9","year":"2022","unstructured":"Blad\u00e9 J et al (2022) Extramedullary disease in multiple myeloma: a systematic literature review. Blood Cancer J 12:45. https:\/\/doi.org\/10.1038\/s41408-022-00643-3","journal-title":"Blood Cancer J"},{"key":"5860_CR25","doi-asserted-by":"publisher","first-page":"300060521106371","DOI":"10.1177\/03000605211063713","volume":"49","author":"W Niu","year":"2021","unstructured":"Niu W et al (2021) Refractory primary extramedullary plasmacytoma in kidney: a case report. J Int Med Res 49:3000605211063713. https:\/\/doi.org\/10.1177\/03000605211063713","journal-title":"J Int Med Res"},{"key":"5860_CR26","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1016\/j.humpath.2020.10.013","volume":"107","author":"S Gupta","year":"2021","unstructured":"Gupta S et al (2021) Renal neoplasia with papillary architecture involving the pelvicalyceal system. Hum Pathol 107:46\u201357. https:\/\/doi.org\/10.1016\/j.humpath.2020.10.013","journal-title":"Hum Pathol"},{"key":"5860_CR27","first-page":"800","volume":"85","author":"F Di Raimondo","year":"2000","unstructured":"Di Raimondo F et al (2000) Angiogenic factors in multiple myeloma: higher levels in bone marrow than in peripheral blood. Haematologica 85:800\u2013805","journal-title":"Haematologica"},{"key":"5860_CR28","doi-asserted-by":"publisher","first-page":"628","DOI":"10.5858\/2000-124-0628-emomms","volume":"124","author":"MA Nandedkar","year":"2000","unstructured":"Nandedkar MA, Abbondanzo SL, Miettinen M (2000) Extramedullary manifestation of multiple myeloma (systemic plasmacytoma) that simulates hemangioma. Arch Pathol Lab Med 124:628\u2013631. https:\/\/doi.org\/10.5858\/2000-124-0628-emomms","journal-title":"Arch Pathol Lab Med"},{"key":"5860_CR29","doi-asserted-by":"publisher","first-page":"661","DOI":"10.1111\/bjh.14291","volume":"175","author":"EG de Waal","year":"2016","unstructured":"de Waal EG et al (2016) Progression of a solitary plasmacytoma to multiple myeloma. A population-based registry of the northern Netherlands. Br J Haematol 175:661\u2013667. https:\/\/doi.org\/10.1111\/bjh.14291","journal-title":"Br J Haematol"},{"key":"5860_CR30","doi-asserted-by":"publisher","unstructured":"Gou MJ et al (2022) Contribution of capillary zone electrophoresis hyphenated with drift tube ion mobility mass spectrometry as a complementary tool to microfluidic reversed phase liquid chromatography for antigen discovery. Int J Mol Sci 23. https:\/\/doi.org\/10.3390\/ijms232113350","DOI":"10.3390\/ijms232113350"},{"key":"5860_CR31","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1016\/j.clinbiochem.2022.05.011","volume":"107","author":"H Cho","year":"2022","unstructured":"Cho H et al (2022) Assessment of M-protein quantification using capillary electrophoresis and immunosubtraction-based integration in clinical samples with low M-protein concentrations. Clin Biochem 107:7\u201312. https:\/\/doi.org\/10.1016\/j.clinbiochem.2022.05.011","journal-title":"Clin Biochem"},{"key":"5860_CR32","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41408-022-00772-9","volume":"13","author":"EK Mai","year":"2023","unstructured":"Mai EK et al (2023) Implications and prognostic impact of mass spectrometry in patients with newly-diagnosed multiple myeloma. Blood Cancer J 13:1. https:\/\/doi.org\/10.1038\/s41408-022-00772-9","journal-title":"Blood Cancer J"},{"key":"5860_CR33","doi-asserted-by":"publisher","first-page":"1358","DOI":"10.1093\/jalm\/jfaa153","volume":"5","author":"G Singh","year":"2020","unstructured":"Singh G (2020) Serum and urine protein electrophoresis and serum-free light chain assays in the diagnosis and monitoring of monoclonal gammopathies. J Appl Lab Med 5:1358\u20131371. https:\/\/doi.org\/10.1093\/jalm\/jfaa153","journal-title":"J Appl Lab Med"},{"key":"5860_CR34","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1093\/ajcp\/aqad137","volume":"161","author":"RS Treger","year":"2024","unstructured":"Treger RS et al (2024) Data analytics improves the diagnostic accuracy of serum free light chain results for detecting monoclonal gammopathy. Am J Clin Pathol 161:216\u2013231. https:\/\/doi.org\/10.1093\/ajcp\/aqad137","journal-title":"Am J Clin Pathol"},{"key":"5860_CR35","unstructured":"Gounden V, Bhatt H, Jialal I (2023) Renal function tests. In: StatPearls [Internet]. StatPearls Publishing, Treasure Island (FL). Available from: https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK507821\/"},{"key":"5860_CR36","doi-asserted-by":"publisher","first-page":"659","DOI":"10.1016\/j.mcna.2023.03.002","volume":"107","author":"K Haq","year":"2023","unstructured":"Haq K, Patel DM (2023) Urinalysis: interpretation and clinical correlations. Med Clin North Am 107:659\u2013679. https:\/\/doi.org\/10.1016\/j.mcna.2023.03.002","journal-title":"Med Clin North Am"},{"key":"5860_CR37","unstructured":"Queremel Milani DA, Jialal I. Urinalysis (2023). In: StatPearls [Internet]. StatPearls Publishing, Treasure Island (FL). Available from: https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK557685\/"},{"key":"5860_CR38","doi-asserted-by":"publisher","first-page":"863","DOI":"10.1007\/s40620-018-0531-1","volume":"31","author":"I Petrucci","year":"2018","unstructured":"Petrucci I, Clementi A, Sessa C, Torrisi I, Meola M (2018) Ultrasound and color Doppler applications in chronic kidney disease. J Nephrol 31:863\u2013879. https:\/\/doi.org\/10.1007\/s40620-018-0531-1","journal-title":"J Nephrol"},{"key":"5860_CR39","doi-asserted-by":"publisher","unstructured":"Hoppe A et al (2021) Risk Factors for catheter-related thrombosis in multiple myeloma patients undergoing autologous stem cell transplantation. Medicina (Kaunas) 57. https:\/\/doi.org\/10.3390\/medicina57101020","DOI":"10.3390\/medicina57101020"},{"key":"5860_CR40","doi-asserted-by":"publisher","first-page":"644","DOI":"10.1182\/blood-2018-08-825356","volume":"133","author":"E Zamagni","year":"2019","unstructured":"Zamagni E, Tacchetti P, Cavo M (2019) Imaging in multiple myeloma: how? When? Blood 133:644\u2013651. https:\/\/doi.org\/10.1182\/blood-2018-08-825356","journal-title":"Blood"},{"key":"5860_CR41","doi-asserted-by":"publisher","first-page":"1743","DOI":"10.1007\/s00256-022-04022-8","volume":"51","author":"CY Chang","year":"2022","unstructured":"Chang CY et al (2022) Society of skeletal radiology- white paper. guidelines for the diagnostic management of incidental solitary bone lesions on CT and MRI in adults: bone reporting and data system (Bone-RADS). Skeletal Radiol 51:1743\u20131764. https:\/\/doi.org\/10.1007\/s00256-022-04022-8","journal-title":"Skeletal Radiol"},{"key":"5860_CR42","doi-asserted-by":"publisher","first-page":"622501","DOI":"10.3389\/fonc.2020.622501","volume":"10","author":"F Matteucci","year":"2020","unstructured":"Matteucci F, Paganelli G, Martinelli G, Cerchione C (2020) PET\/CT in multiple myeloma: beyond FDG. Front Oncol 10:622501. https:\/\/doi.org\/10.3389\/fonc.2020.622501","journal-title":"Front Oncol"},{"key":"5860_CR43","doi-asserted-by":"publisher","first-page":"e302","DOI":"10.1016\/s1470-2045(19)30309-2","volume":"20","author":"J Hillengass","year":"2019","unstructured":"Hillengass J et al (2019) International myeloma working group consensus recommendations on imaging in monoclonal plasma cell disorders. Lancet Oncol 20:e302\u2013e312. https:\/\/doi.org\/10.1016\/s1470-2045(19)30309-2","journal-title":"Lancet Oncol"},{"key":"5860_CR44","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1093\/ndt\/gfv283","volume":"31","author":"L Ecoti\u00e8re","year":"2016","unstructured":"Ecoti\u00e8re L et al (2016) Prognostic value of kidney biopsy in myeloma cast nephropathy: a retrospective study of 70 patients. Nephrol Dial Transplant 31:64\u201372. https:\/\/doi.org\/10.1093\/ndt\/gfv283","journal-title":"Nephrol Dial Transplant"},{"key":"5860_CR45","doi-asserted-by":"publisher","first-page":"1281","DOI":"10.6004\/jnccn.2023.0061","volume":"21","author":"SK Kumar","year":"2023","unstructured":"Kumar SK et al (2023) Multiple myeloma, version 2.2024, NCCN clinical practice guidelines in oncology. J Natl Compr Canc Netw 21:1281\u20131301. https:\/\/doi.org\/10.6004\/jnccn.2023.0061","journal-title":"J Natl Compr Canc Netw"},{"key":"5860_CR46","doi-asserted-by":"publisher","first-page":"959","DOI":"10.1038\/s41409-022-01657-y","volume":"57","author":"I Lazana","year":"2022","unstructured":"Lazana I et al (2022) Autologous stem cell transplantation for multiple myeloma patients with chronic kidney disease: a safe and effective option. Bone Marrow Transplant 57:959\u2013965. https:\/\/doi.org\/10.1038\/s41409-022-01657-y","journal-title":"Bone Marrow Transplant"},{"key":"5860_CR47","doi-asserted-by":"publisher","first-page":"578","DOI":"10.1038\/s41409-019-0697-8","volume":"55","author":"AY Li","year":"2020","unstructured":"Li AY et al (2020) Toxicity and survival outcomes of autologous stem cell transplant in multiple myeloma patients with renal insufficiency: an institutional comparison between two eras. Bone Marrow Transplant 55:578\u2013585. https:\/\/doi.org\/10.1038\/s41409-019-0697-8","journal-title":"Bone Marrow Transplant"},{"key":"5860_CR48","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1038\/s41408-022-00645-1","volume":"12","author":"AH Bazarbachi","year":"2022","unstructured":"Bazarbachi AH et al (2022) Induction therapy prior to autologous stem cell transplantation (ASCT) in newly diagnosed multiple myeloma: an update. Blood Cancer J 12:47. https:\/\/doi.org\/10.1038\/s41408-022-00645-1","journal-title":"Blood Cancer J"},{"key":"5860_CR49","doi-asserted-by":"publisher","first-page":"4962","DOI":"10.1182\/blood-2023-174479","volume":"142","author":"O Pasvolsky","year":"2023","unstructured":"Pasvolsky O, Marcoux C, Dai J, Milton DR, Tanner MR, Syed N, Bashir Q, Srour SA, Saini NY, Lin P, Ramdial J, Nieto Y, Lee HC, Patel KK, Manasanch EE, Kebriaei P, Thomas SK, Weber DM, Orlowski RZ, Shpall EJ, Champlin RE, Qazilbash MH (2023) Trends in outcomes over three decades after upfront autologous stem cell transplant for multiple myeloma at MD Anderson Cancer Center. Blood 142:4962. https:\/\/doi.org\/10.1182\/blood-2023-174479","journal-title":"Blood"},{"key":"5860_CR50","doi-asserted-by":"publisher","first-page":"2022","DOI":"10.1182\/hematology.2022000334","volume":"163\u2013172","author":"C Cipkar","year":"2022","unstructured":"Cipkar C, Chen C, Trudel S (2022) Antibodies and bispecifics for multiple myeloma: effective effector therapy. Hematology Am Soc Hematol Educ Program 163\u2013172:2022. https:\/\/doi.org\/10.1182\/hematology.2022000334","journal-title":"Hematology Am Soc Hematol Educ Program"},{"key":"5860_CR51","doi-asserted-by":"publisher","first-page":"568","DOI":"10.1200\/jco.21.02815","volume":"41","author":"MA Dimopoulos","year":"2023","unstructured":"Dimopoulos MA et al (2023) Elotuzumab plus pomalidomide and dexamethasone for relapsed\/refractory multiple myeloma: final overall survival analysis from the randomized phase II ELOQUENT-3 trial. J Clin Oncol 41:568\u2013578. https:\/\/doi.org\/10.1200\/jco.21.02815","journal-title":"J Clin Oncol"},{"key":"5860_CR52","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1038\/s41408-023-00797-8","volume":"13","author":"T Martin","year":"2023","unstructured":"Martin T et al (2023) Isatuximab, carfilzomib, and dexamethasone in patients with relapsed multiple myeloma: updated results from IKEMA, a randomized phase 3 study. Blood Cancer J 13:72. https:\/\/doi.org\/10.1038\/s41408-023-00797-8","journal-title":"Blood Cancer J"},{"key":"5860_CR53","doi-asserted-by":"publisher","first-page":"1616","DOI":"10.1093\/ndt\/gfaa361","volume":"37","author":"DW Chitty","year":"2022","unstructured":"Chitty DW et al (2022) Kidney transplantation in patients with multiple myeloma: narrative analysis and review of the last two decades. Nephrol Dial Transplant 37:1616\u20131626. https:\/\/doi.org\/10.1093\/ndt\/gfaa361","journal-title":"Nephrol Dial Transplant"},{"key":"5860_CR54","doi-asserted-by":"publisher","first-page":"2423","DOI":"10.1182\/blood.2022016170","volume":"140","author":"B Paiva","year":"2022","unstructured":"Paiva B, San-Miguel J, Avet-Loiseau H (2022) MRD in multiple myeloma: does CR really matter? Blood 140:2423\u20132428. https:\/\/doi.org\/10.1182\/blood.2022016170","journal-title":"Blood"},{"key":"5860_CR55","doi-asserted-by":"publisher","first-page":"e293","DOI":"10.1016\/s1470-2045(23)00223-1","volume":"24","author":"MA Dimopoulos","year":"2023","unstructured":"Dimopoulos MA et al (2023) Management of multiple myeloma-related renal impairment: recommendations from the International Myeloma Working Group. Lancet Oncol 24:e293\u2013e311. https:\/\/doi.org\/10.1016\/s1470-2045(23)00223-1","journal-title":"Lancet Oncol"},{"key":"5860_CR56","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1016\/j.ejim.2022.05.003","volume":"101","author":"N Klomjit","year":"2022","unstructured":"Klomjit N, Ungprasert P (2022) Acute kidney injury associated with non-steroidal anti-inflammatory drugs. Eur J Intern Med 101:21\u201328. https:\/\/doi.org\/10.1016\/j.ejim.2022.05.003","journal-title":"Eur J Intern Med"},{"key":"5860_CR57","doi-asserted-by":"publisher","unstructured":"Petejova N et al (2020) Acute kidney injury in septic patients treated by selected nephrotoxic antibiotic agents-pathophysiology and biomarkers-a review. Int J Mol Sci 21. https:\/\/doi.org\/10.3390\/ijms21197115","DOI":"10.3390\/ijms21197115"},{"key":"5860_CR58","doi-asserted-by":"publisher","first-page":"1234","DOI":"10.2215\/cjn.16311221","volume":"17","author":"W Cashion","year":"2022","unstructured":"Cashion W, Weisbord SD (2022) Radiographic contrast media and the kidney. Clin J Am Soc Nephrol 17:1234\u20131242. https:\/\/doi.org\/10.2215\/cjn.16311221","journal-title":"Clin J Am Soc Nephrol"},{"key":"5860_CR59","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1038\/s41571-023-00754-1","volume":"20","author":"KM Cappell","year":"2023","unstructured":"Cappell KM, Kochenderfer JN (2023) Long-term outcomes following CAR T cell therapy: what we know so far. Nat Rev Clin Oncol 20:359\u2013371. https:\/\/doi.org\/10.1038\/s41571-023-00754-1","journal-title":"Nat Rev Clin Oncol"},{"key":"5860_CR60","doi-asserted-by":"publisher","first-page":"e446","DOI":"10.1016\/s2352-3026(21)00057-0","volume":"8","author":"N van de Donk","year":"2021","unstructured":"van de Donk N, Usmani SZ, Yong K (2021) CAR T-cell therapy for multiple myeloma: state of the art and prospects. Lancet Haematol 8:e446\u2013e461. https:\/\/doi.org\/10.1016\/s2352-3026(21)00057-0","journal-title":"Lancet Haematol"},{"key":"5860_CR61","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1016\/j.ccell.2023.02.008","volume":"41","author":"MJ Friedrich","year":"2023","unstructured":"Friedrich MJ et al (2023) The pre-existing T cell landscape determines the response to bispecific T cell engagers in multiple myeloma patients. Cancer Cell 41:711-725.e716. https:\/\/doi.org\/10.1016\/j.ccell.2023.02.008","journal-title":"Cancer Cell"},{"issue":"Suppl 2","key":"5860_CR62","doi-asserted-by":"publisher","first-page":"S13","DOI":"10.1002\/ajh.26628","volume":"98","author":"G Ravi","year":"2023","unstructured":"Ravi G, Costa LJ (2023) Bispecific T-cell engagers for treatment of multiple myeloma. Am J Hematol 98(Suppl 2):S13-s21. https:\/\/doi.org\/10.1002\/ajh.26628","journal-title":"Am J Hematol"},{"key":"5860_CR63","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1038\/s41571-020-00442-4","volume":"18","author":"AS Azmi","year":"2021","unstructured":"Azmi AS, Uddin MH, Mohammad RM (2021) The nuclear export protein XPO1 - from biology to targeted therapy. Nat Rev Clin Oncol 18:152\u2013169. https:\/\/doi.org\/10.1038\/s41571-020-00442-4","journal-title":"Nat Rev Clin Oncol"},{"key":"5860_CR64","doi-asserted-by":"publisher","first-page":"727","DOI":"10.1056\/NEJMoa1903455","volume":"381","author":"A Chari","year":"2019","unstructured":"Chari A et al (2019) Oral selinexor-dexamethasone for triple-class refractory multiple myeloma. N Engl J Med 381:727\u2013738. https:\/\/doi.org\/10.1056\/NEJMoa1903455","journal-title":"N Engl J Med"},{"key":"5860_CR65","doi-asserted-by":"publisher","first-page":"2232","DOI":"10.1056\/NEJMoa2204591","volume":"387","author":"A Chari","year":"2022","unstructured":"Chari A et al (2022) Talquetamab, a T-cell-redirecting GPRC5D bispecific antibody for multiple myeloma. N Engl J Med 387:2232\u20132244. https:\/\/doi.org\/10.1056\/NEJMoa2204591","journal-title":"N Engl J Med"},{"key":"5860_CR66","doi-asserted-by":"publisher","first-page":"e255","DOI":"10.1016\/s1470-2045(23)00159-6","volume":"24","author":"H Ludwig","year":"2023","unstructured":"Ludwig H et al (2023) Prevention and management of adverse events during treatment with bispecific antibodies and CAR T cells in multiple myeloma: a consensus report of the European Myeloma Network. Lancet Oncol 24:e255\u2013e269. https:\/\/doi.org\/10.1016\/s1470-2045(23)00159-6","journal-title":"Lancet Oncol"},{"key":"5860_CR67","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1186\/s13045-019-0786-6","volume":"12","author":"B Yu","year":"2019","unstructured":"Yu B, Liu D (2019) Antibody-drug conjugates in clinical trials for lymphoid malignancies and multiple myeloma. J Hematol Oncol 12:94. https:\/\/doi.org\/10.1186\/s13045-019-0786-6","journal-title":"J Hematol Oncol"},{"key":"5860_CR68","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1016\/s1470-2045(19)30788-0","volume":"21","author":"S Lonial","year":"2020","unstructured":"Lonial S et al (2020) Belantamab mafodotin for relapsed or refractory multiple myeloma (DREAMM-2): a two-arm, randomised, open-label, phase 2 study. Lancet Oncol 21:207\u2013221. https:\/\/doi.org\/10.1016\/s1470-2045(19)30788-0","journal-title":"Lancet Oncol"},{"key":"5860_CR69","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1186\/s40164-023-00456-5","volume":"12","author":"Z Liu","year":"2023","unstructured":"Liu Z et al (2023) Immune checkpoint inhibitors for multiple myeloma immunotherapy. Exp Hematol Oncol 12:99. https:\/\/doi.org\/10.1186\/s40164-023-00456-5","journal-title":"Exp Hematol Oncol"},{"key":"5860_CR70","doi-asserted-by":"publisher","unstructured":"Alkharabsheh O, Trisel Z, Badami S, Aljama MA, Sidiqi MH (2021) Checkpoint inhibitors in multiple myeloma: intriguing potential and unfulfilled promises. Cancers (Basel) 14. https:\/\/doi.org\/10.3390\/cancers14010113","DOI":"10.3390\/cancers14010113"},{"key":"5860_CR71","doi-asserted-by":"publisher","first-page":"1009","DOI":"10.1038\/s41467-022-28515-1","volume":"13","author":"YLD Ng","year":"2022","unstructured":"Ng YLD et al (2022) Proteomic profiling reveals CDK6 upregulation as a targetable resistance mechanism for lenalidomide in multiple myeloma. Nat Commun 13:1009. https:\/\/doi.org\/10.1038\/s41467-022-28515-1","journal-title":"Nat Commun"}],"container-title":["Annals of Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-024-05860-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00277-024-05860-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-024-05860-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,3]],"date-time":"2025-01-03T01:06:26Z","timestamp":1735866386000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00277-024-05860-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,6,28]]},"references-count":71,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2024,12]]}},"alternative-id":["5860"],"URL":"https:\/\/doi.org\/10.1007\/s00277-024-05860-3","relation":{},"ISSN":["0939-5555","1432-0584"],"issn-type":[{"value":"0939-5555","type":"print"},{"value":"1432-0584","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,6,28]]},"assertion":[{"value":"10 April 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 June 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 June 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}